Guzek Aneta, Tomaszewski Dariusz, Rybicki Zbigniew, Truszczyński Andrzej, Barański Mariusz, Korzeniewski Krzysztof
Microbiology Research Unit, Department of Laboratory Diagnostics, Military Institute of Medicine in Warsaw, Poland.
Anaesthesiol Intensive Ther. 2013 Apr-Jun;45(2):67-72. doi: 10.5603/AIT.2013.0015.
The members of the bacterial Enterobacteriaceae family play an important role in the aetiology of many hospital infections. Some of them are able to produce β-lactamase, an enzyme which induces the resistance of those bacteria to penicillins, cephalosporins and, in severe infections, to penicillins with β-lactamase inhibitors. In this situation, the carbapenems become the drugs of choice. The objective of this study was to analyse the in vitro efficacy of three carbapenems: ertapenem, imipenem and meropenem against bacterial species of the Enterobacteriaceae family.
A total of 99 bacterial species (including ten bacterial species producing the ESBL mechanism), isolated between September 2011 and March 2012 from diagnostic material collected from patients of surgical clinics in the department of motoskeletal system infections and the critical care unit, hospitalised in the Military Institute of Medicine in Warsaw, were analysed. The values of MIC 50 and MIC 90 were recorded.
All isolated bacterial species were susceptible to meropenem. One strain of Morganella morganii was resistant to imipenem, while one strain of Enterobacter cloaceae and one strain of Klebsiella pneumoniae were resistant to ertapenem. In the Enterobacteriaceae ESBL(-) group, the values of MIC 50 were 0.006 μg mL-1 for ertapenem, 0.19 μg mL⁻¹ for imipenem, and 0.032 μg mL⁻¹ for meropenem, and the MIC 90 values were: 0.25 μg mL⁻¹, 0.5 μg mL⁻¹ and 0.125 μg mL⁻¹, respectively. In the Enterobacteriaceae ESBL(+) group, the values of MIC 50 were 0.38 μg mL⁻¹, 0.25 μg mL⁻¹, 0.064 μg mL⁻¹, and the values of MIC 90 were 0.5 μg mL⁻¹, 0.25 μg mL⁻¹ and 0.125 μg mL⁻¹, respectively.
All analysed carbapenems had high in vitro efficacy against both Enterobacteriaceae ESBL(-) and Enterobacteriaceae ESBL(+) bacterial species.
肠杆菌科细菌成员在许多医院感染的病因学中起重要作用。其中一些能够产生β-内酰胺酶，这种酶会使这些细菌对青霉素、头孢菌素产生耐药性，在严重感染时，对含β-内酰胺酶抑制剂的青霉素也产生耐药性。在这种情况下，碳青霉烯类药物成为首选药物。本研究的目的是分析三种碳青霉烯类药物：厄他培南、亚胺培南和美罗培南对肠杆菌科细菌的体外抗菌效果。
分析了2011年9月至2012年3月期间从华沙军事医学研究所肌肉骨骼系统感染外科诊所和重症监护病房患者的诊断材料中分离出的99种细菌（包括10种产生超广谱β-内酰胺酶机制的细菌）。记录了MIC50和MIC90的值。
所有分离出的细菌对美罗培南均敏感。一株摩根摩根菌对亚胺培南耐药，一株阴沟肠杆菌和一株肺炎克雷伯菌对厄他培南耐药。在肠杆菌科ESBL（-）组中，厄他培南的MIC50值为0.006μg/mL，亚胺培南为0.19μg/mL，美罗培南为0.032μg/mL，MIC90值分别为：0.25μg/mL、0.5μg/mL和0.125μg/mL。在肠杆菌科ESBL（+）组中，MIC50值分别为0.38μg/mL、0.25μg/mL、0.064μg/mL，MIC90值分别为0.5μg/mL、0.25μg/mL和0.125μg/mL。
所有分析的碳青霉烯类药物对肠杆菌科ESBL（-）和肠杆菌科ESBL（+）细菌均具有较高的体外抗菌效果。
